A PHASE-II TRIAL OF DIDEMNIN-B (NSC-NUMBER-335319) IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX A GYNECOLOGIC-ONCOLOGY-GROUP STUDY - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY

Didemnin B (NSC #335319) was administered i.v. to 26 evaluable patient s with advanced, persistent, or recurrent squamous cell carcinoma of t he cervix at 6.3 mg/m(2) every 28 days until progression of disease. N o patient had had prior cytotoxic therapy alone. Some patients (4) wer e exposed to radiation sensitizers. There was one complete responder ( 4.5%). Six patients had stable disease (27.3%) and 15 (68.2%) had incr easing disease. The toxicities were significant, with 11 patients (42. 3%) experiencing grade 3 or 4 adverse effects. Didemnin B, when used w ith this dose and schedule, has minimal activity in squamous cell carc inoma of the cervix.